Description: Vaxart, Inc., a clinical-stage company, focuses on developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company's platform delivers various recombinant protein antigens, such as those used in influenza, hepatitis B, and human papilloma virus (HPV) vaccines, as well as other recombinant vaccines. Its development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus, as well as a therapeutic vaccine for HPV. The company is headquartered in South San Francisco, California.
Home Page: vaxart.com
VXRT Technical Analysis
170 Harbor Way
South San Francisco,
CA
94080
United States
Phone:
650 550 3500
Officers
| Name | Title |
|---|---|
| Mr. Cezar Andrei Floroiu M.B.A. | CEO, Pres & Director |
| Dr. Sean N. Tucker | Sr. VP & Chief Scientific Officer |
| Dr. James F. Cummings M.D. | Chief Medical Officer |
| Mr. Fuad Ahmad | Interim CFO and Principal Financial & Accounting Officer |
| Dr. Raymond D. Stapleton Jr., Ph.D. | Chief Technology Officer |
| Mr. Edward B. Berg | Sr. VP & Gen. Counsel |
| Ms. Shaily Jaini Garg | Sr. VP of Clinical Devel. & Project Management |
| Mr. Brant Biehn | Sr. VP of Bus. Operations |
| Dr. Rajesh Kapoor Ph.D. | Sr. VP of Quality |
| Mr. John M. Harland M.B.A., CPA | Consultant |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 42.735 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.1053 |
| Price-to-Sales TTM: | 916.2665 |
| IPO Date: | 2018-02-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 110 |